• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Aligos Therapeutics Inc.

    4/29/26 4:33:53 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALGS alert in real time by email
    DEFA14A 1 d122092ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.)

     

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    ALIGOS THERAPEUTICS, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    C/O TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Aligos Therapeutics, Inc. Meeting To Be Held On June 25, 2026 For Stockholders of record as of April 27, 2026 Annual Meeting of Stockholders To order paper materials, use one of the Thursday, June 25, 2026 8:00 AM, Pacific Time Annual Meeting to be held live via the internet—Please visit www.proxydocs.com/ALGS for following methods. more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/ALGS no later than June 24, 2026 at 5:00 p.m. Eastern Time. Internet: For a convenient way to view proxy materials, VOTE, and obtain www.investorelections.com/ALGS directions to attend the meeting go to www.proxydocs.com/ALGS To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Call: 1-866-648-8133 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Email: paper@investorelections.com Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the * If requesting material by e-mail, please send a blank e-mail with the internet. 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your If you want to receive a paper or e-mail copy of the proxy material, you must request one. e-mail requesting material. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 15, 2026. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved 


    LOGO

    Aligos Therapeutics, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE:    FOR PROPOSALS 1, 2, 3 AND 4 1 YEAR FOR PROPOSAL 5 PROPOSAL 1. To elect two Class III directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected; 1.01 Bridget Martell, M.A., M.D. 1.02 Carole Nuechterlein, J.D. 2. To ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; 3. To approve an amendment to the Company’s 2020 Employee Stock Purchase Plan (the “ESPP”), in substantially the form attached to the accompanying Proxy Statement as Appendix A, to remove the evergreen provision and increase the number of shares reserved for issuance under the ESPP by 500,000 shares; 4. To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission (“Say-on-Pay”); and 5. To approve, on a non-binding, advisory basis, whether a Say-on-Pay vote should occur every one year, every two years or every three years. NOTE: In addition, you are entitled to vote on any other matters that are properly brought before the Annual Meeting.

    Get the next $ALGS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGS

    DatePrice TargetRatingAnalyst
    5/28/2026$45.00Buy
    Lake Street
    5/21/2026$20.00Overweight
    Cantor Fitzgerald
    3/19/2026$48.00Buy
    Jefferies
    8/18/2025$50.00Buy
    H.C. Wainwright
    8/19/2024$75.00Buy
    H.C. Wainwright
    1/6/2023$2.00 → $3.00Neutral → Overweight
    Piper Sandler
    1/6/2023$2.50 → $3.00Hold → Buy
    Jefferies
    3/23/2022$15.00 → $4.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ALGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Aligos Therapeutics with a new price target

    Lake Street initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $45.00

    5/28/26 8:42:17 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Aligos Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Aligos Therapeutics with a rating of Overweight and set a new price target of $20.00

    5/21/26 8:06:56 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies resumed coverage on Aligos Therapeutics with a new price target

    Jefferies resumed coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $48.00

    3/19/26 8:25:43 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Aligos Therapeutics Inc.

    SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    5/15/26 9:05:48 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Aligos Therapeutics Inc.

    10-Q - Aligos Therapeutics, Inc. (0001799448) (Filer)

    5/7/26 4:18:52 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)

    5/7/26 4:08:02 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

    Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented40% of HBeAg+ participants with chronic HBV infection treated with pevifoscorvir sodium at week 48 had reductions in HBsAg that would potentially allow them to qualify for ASO treatment SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from ten presentat

    5/27/26 2:30:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

    SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/. Details on the abstracts are as follows: Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) inf

    5/13/26 2:05:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2026. "I am pleased to continue building on our progress made so far in 2026," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "Receiving Fast Track Designation is confirmation that an unmet medical need exists in chronic HBV infection and pevifoscorvir sodium has the potential to be superior to

    5/7/26 4:05:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Symons Julian A.

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    3/11/26 4:19:59 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Aligos Therapeutics Inc.

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    3/11/26 4:13:30 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Aligos Therapeutics Inc.

    4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    3/11/26 4:13:06 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Leadership Updates

    Live Leadership Updates

    View All

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (("Aligos", NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Company's global commercial capabilities and serve as a member of Aligos' Senior Leadership Team. Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas. "As we continue to progress the Phase 2 B-

    1/13/26 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

    SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. "I am thrilled to welcome Ramón to the leadership team at Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "As we progress ALG-000184 through the Phase 2 B-SUPREME study, Ramón's extensive regulatory expertise will be a critical component as we th

    8/20/25 8:30:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

    SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately. "I am pleased to welcome Kieron to Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "With decades of experience, Kieron's extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all CMC-related matters."

    6/18/25 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:57:50 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:19:11 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 5:03:16 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    Financials

    Live finance-specific insights

    View All

    Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

    ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B were observedConference call scheduled for 8:30am ET/5:30am PT today SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alig

    9/19/24 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

    SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company"))), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. Conference Call & Webcast Details Th

    9/18/24 5:00:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

    CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos' proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient

    3/10/22 4:05:00 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care